|
Jun 17
|
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
|
|
Jun 17
|
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
|
|
Jun 16
|
Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy
|
|
Jun 16
|
Genentech Provides Update on Phase III Verona Study
|
|
Jun 16
|
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
|
|
Jun 16
|
Sarepta and Roche halt DMD gene therapy’s use after second death
|
|
Jun 16
|
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
|
|
Jun 16
|
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
|
|
Jun 15
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
|
|
Jun 13
|
Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 11
|
Video: Trump's Drug Pricing Order Threatens Investment, Says Roche CEO
|
|
May 31
|
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
|
|
May 31
|
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
|
|
May 30
|
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years
|
|
May 30
|
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
|
|
May 30
|
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
|
|
May 29
|
This new antibiotic may finally put a stop to some of the world’s most drug-resistant pathogens
|
|
May 29
|
The Zacks Analyst Blog Highlights Alphabet, Bank of America, Roche, Village Super Market and Aware
|
|
May 28
|
Top Analyst Reports for Alphabet, Bank of America & Roche
|